Hydrophilic iminosugar active-site-specific chaperones increase residual glucocerebrosidase activity in fibroblasts from Gaucher patients.
Gaucher disease is an autosomal recessive lysosomal storage disorder caused by the deficient activity of glucocerebrosidase. Accumulation of glucosylceramide, primarily in the lysosomes of cells of the reticuloendothelial system, leads to hepatosplenomegaly, anemia and skeletal lesions in type I disease, and neurologic manifestations in types II and III disease. We report herein the identification of hydrophilic active-site-specific chaperones that are capable of increasing glucocerebrosidase activity in the cultured fibroblasts of Gaucher patients. Screening of a variety of natural and synthetic alkaloid compounds showed isofagomine, N-dodecyl deoxynojirimycin, calystegines A3, B1, B2 and C1, and 1,5-dideoxy-1,5-iminoxylitol to be potent inhibitors of glucocerebrosidase. Among them, isofagomine was the most potent inhibitor of glucocerebrosidase in vitro, and the most effective active-site-specific chaperone capable of increasing residual glucocerebrosidase activity in fibroblasts established from Gaucher patients with the most prevalent Gaucher disease-causing mutation (N370S). Intracellular enzyme activity increased approximately two-fold after cells had been incubated with isofagomine, and the increase in glucocerebrosidase activity was both dose-dependent and time-dependent. Western blotting demonstrated that there was a substantial increase in glucocerebrosidase protein in cells after isofagomine treatment. Immunocytochemistry revealed an improvement in the glucocerebrosidase trafficking pattern, which overlaps that of lysosome-associated membrane protein 2 in Gaucher fibroblasts cultivated with isofagomine, suggesting that the transport of mutant glucocerebrosidase is at least partially improved in the presence of isofagomine. The hydrophilic active-site-specific chaperones are less toxic to cultured cells. These results indicate that these hydrophilic small molecules are suitable candidates for further drug development for the treatment of Gaucher disease.
Chang
Hui-Hwa
HH
Department of Human Genetics, Mount Sinai School of Medicine, New York, NY 10029, USA.
Asano
Naoki
N
Ishii
Satoshi
S
Ichikawa
Yoshitaka
Y
Fan
Jian-Qiang
JQ
D019943:Amino Acid Substitution / Q000235:genetics; D001216:Asparagine / Q000235:genetics; D001665:Binding Sites; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000737:chemistry; D005347:Fibroblasts / Q000201:enzymology*; D005776:Gaucher Disease / Q000201:enzymology* / Q000235:genetics / Q000628:therapy; D005962:Glucosylceramidase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D006801:Humans; D050111:Imino Sugars / Q000378:metabolism*; D018832:Molecular Chaperones / Q000502:physiology*; D012694:Serine / Q000235:genetics
D004791:Enzyme Inhibitors; D050111:Imino Sugars; D018832:Molecular Chaperones; D012694:Serine; D001216:Asparagine; D005962:Glucosylceramidase